Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?
Cristina Stasi, Barbara Meoni, Fabio Voller, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 444-444
Open Access | Times Cited: 17

Showing 17 citing articles:

Evidence-Based Policies in Public Health to Address COVID-19 Vaccine Hesitancy
Francesco Chirico, Jaime A. Teixeira da Silva
Future Virology (2023) Vol. 18, Iss. 4, pp. 261-273
Open Access | Times Cited: 21
Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review
Silvia Martinelli, Domenico Pascucci, Patrizia Laurenti
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 20
B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
Younes Bathish, Neta Tuvia, Elizabeth Eshel, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort
Daniele Mauro, Antonio Ciancio, Claudio Di Vico, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance
Monica Franzese, Luigi Coppola, Romina Silva, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort
Manuela Rizzi, Stelvio Tonello, Cristiana Brinno, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Head CT Scans in the Emergency Department during the COVID-19 Pandemic: Use or Overuse?
Marcello Covino, Andrea Piccioni, Giuseppe Merra, et al.
Life (2024) Vol. 14, Iss. 2, pp. 264-264
Open Access | Times Cited: 1
The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China
Wei Qin, Xiaqing Zhang, Xiaojing Yao, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 7
Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study
Qiu‐Yan Xu, Qiuling Li, Zhi-Juan Jia, et al.
Journal of Infection (2022) Vol. 85, Iss. 3, pp. e66-e68
Open Access | Times Cited: 5
Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan
Zunera Jamal, Murtaza Haider, Aamer Ikram, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 5
Recent developments in the therapeutics of SARS-CoV-2 infection
Priyanka Nagu, Arun Parashar, Pankaj Sharma, et al.
One Health Bulletin (2024) Vol. 4, Iss. 4, pp. 143-156
Open Access
Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Pattriya Jirawattanadon, Charussri Leeyaphan, Pornpan Koomanachai, et al.
Clinical and Experimental Vaccine Research (2024) Vol. 13, Iss. 4, pp. 309-309
Open Access
Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study
Qiu‐Yan Xu, Xin‐Qi Zheng, Zhi-Juan Jia, et al.
Journal of Infection (2022) Vol. 86, Iss. 2, pp. e55-e57
Open Access | Times Cited: 3
Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
PubMed (2022) Vol. 14, Iss. 4, pp. 272-275
Closed Access | Times Cited: 3
Cross-Reactivity between Half Doses of Pfizer and AstraZeneca Vaccines—A Preliminary Study
Krzysztof Łukaszuk, Amira Podolak, Paulina Malinowska, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 521-521
Open Access | Times Cited: 2
ENERGIAS LIVRES DE LIGAÇÃO ABSOLUTA DO PEPTÍDEO ANTIVIRAL ATN-161 COM ALVOS PROTEICOS DE SARS-COV-2
RUDIELSON DOS SANTOS SILVA
(2023)
Open Access
Immunization against COVID-19: A Comprehensive Review on the Leading Vaccines
Ananyaa Srinivasan, Vijaishree Rajesh, Dharani Thamilvanan, et al.
Coronaviruses (2023) Vol. 5, Iss. 4
Closed Access
Page 1

Scroll to top